In early-stage, clinically node-negative breast cancer (tumors ≤3 cm), how do the SOUND trial and the INSEMA trial compare regarding the safety of omitting sentinel lymph node biopsy?

SOUND vs INSEMA Trial Comparison in Early-Stage Breast Cancer

Direct Answer

Both the SOUND and INSEMA trials demonstrate that sentinel lymph node biopsy (SLNB) can be safely omitted in carefully selected patients with early-stage, clinically node-negative breast cancer, with INSEMA providing broader applicability but SOUND offering stricter selection criteria that may be more appropriate for initial implementation. 1

---

Key Trial Differences

Patient Population & Tumor Size

SOUND Trial:

• Stricter inclusion: tumors ≤2 cm only (median 1.1 cm)
• 1,405 patients randomized
• Primary endpoint: distant disease-free survival (DDFS)
• 5-year follow-up data 1

INSEMA Trial:

• Broader inclusion: T1 or T2 tumors (≤5 cm)
• 5,502 patients randomized (much larger)
• 90% had clinical T1, 79% had pathological T1
• Primary endpoint: invasive disease-free survival (IDFS)
• 73.6 months median follow-up (approximately 6 years) 1, 2

Oncologic Outcomes - Both Trials Show Safety

SOUND Results:

• 5-year DDFS: no difference between groups
• Axillary recurrence: 1.7% (SLNB) vs 1.6% (no surgery) 1

INSEMA Results:

• 5-year IDFS: 91.9% (no surgery) vs 91.7% (SLNB)
• Hazard ratio 0.91 (95% CI 0.73-1.14) - met noninferiority
• Axillary recurrence: 1.0% (no surgery) vs 0.3% (SLNB)
• Death: 1.4% (no surgery) vs 2.4% (SLNB) 1, 2

Quality of Life Benefits - INSEMA Provides Detailed Data

INSEMA demonstrated significantly superior patient-reported outcomes in the no-surgery group: 1

• Lymphedema: 1.8% vs 5.7% (69% reduction)
• Arm/shoulder mobility restriction: 2.0% vs 3.5%
• Pain with arm/shoulder movement: 2.0% vs 4.2%

SOUND showed similarly low local-regional relapse but did not report detailed quality-of-life metrics in the guideline excerpts.

---

Critical Population Characteristics

Well-Represented (Safe to Apply)

Both trials predominantly included:

• Postmenopausal women (78.7% in SOUND, 89.2% in INSEMA)
• Hormone receptor-positive/HER2-negative tumors (93% in SOUND)
• Invasive ductal carcinoma
• Low-grade tumors (grade 3: 18% SOUND, 3.6% INSEMA) 1

Underrepresented (Use Caution)

Exercise caution when applying SLNB omission to: 1

• Age <50 years (18.6% SOUND, 10.8% INSEMA)
• Premenopausal patients (21.3% SOUND)
• Grade 3 tumors (18% SOUND, 3.6% INSEMA)
• High Ki-67 (≥20%: 36% SOUND; >20%: 12.9% INSEMA)
• Invasive lobular carcinoma (8.5% SOUND, 12.7% INSEMA)
• HER2-positive (6.8% SOUND, 3.6% INSEMA)
• Triple-negative breast cancer (5.4% SOUND, 1.2% INSEMA)

---

Radiation Therapy Considerations

Critical Context

Both trials required breast-conserving surgery with radiation therapy: 1

• SOUND: >80% received whole-breast irradiation (WBI)
• INSEMA: No patients received partial breast irradiation (PBI)
• Regional nodal irradiation was NOT routinely used
• Only 13.1% (SOUND) and 14.9% (INSEMA) had positive nodes when SLNB was performed

This means: The low nodal positivity rate suggests most patients would not have required regional nodal RT regardless, making SLNB omission oncologically safe in this context.

---

Axillary Ultrasound Requirements

Mandatory Pre-Surgical Imaging

Both trials required negative preoperative axillary ultrasound: 1

• If one suspicious node visualized → FNA required (must be negative)
• INSEMA also allowed core needle biopsy
• FNA is preferred over core biopsy (less pain, lower cost, adequate sensitivity)
• Biopsy must be both benign AND concordant on ultrasound

Nodal Upstaging Rates When SLNB Performed

• SOUND: 13.1% had 1-3 positive nodes, 0.6% had ≥4 positive nodes 1
• INSEMA: 14.9% had pN1 disease, 0.2% had pN2 disease 1

---

Clinical Implementation Algorithm

Step 1: Confirm Eligibility Criteria

Mandatory requirements (both trials):

1. Clinically node-negative (cN0) on physical exam
2. Negative axillary ultrasound (or single suspicious node negative on FNA)
3. Planned breast-conserving surgery + radiation therapy
4. No neoadjuvant chemotherapy

Tumor size:

• SOUND criteria (stricter): ≤2 cm
• INSEMA criteria (broader): ≤5 cm (but 90% were T1)

Step 2: Assess Tumor Biology

Ideal candidates (strongly consider SLNB omission):

• Postmenopausal
• Hormone receptor-positive/HER2-negative
• Grade 1-2
• Invasive ductal carcinoma
• Low Ki-67 (<20%)

Proceed with caution (consider SLNB):

• Premenopausal or age <50
• Grade 3 tumors
• High Ki-67 (≥20%)
• Invasive lobular carcinoma
• HER2-positive or triple-negative

Step 3: Confirm Radiation Plan

• Whole-breast irradiation planned
• Regional nodal irradiation NOT indicated based on clinical staging
• Patient suitable for standard adjuvant RT

---

Common Pitfalls to Avoid

1. Do not apply to mastectomy patients - Both trials required breast-conserving surgery 1

2. Do not skip axillary ultrasound - Negative imaging is mandatory, not optional 1

3. Do not extrapolate to aggressive subtypes - Triple-negative and HER2-positive were severely underrepresented 1

4. Do not omit in neoadjuvant setting - These trials were upfront surgery only 1

5. MRI not routinely used - If performed, can help confirm tumor size ≤2 cm for SOUND criteria 1

---

Guideline Recommendations

The 2025 ASCO Guideline Update endorses SLNB omission based on both trials 1, with recommendations focused on populations well-represented in the studies.

The 2025 NCCN Guidelines added a footnote specifically citing SOUND: "Patients with HR-positive/HER2-negative tumors, T1, N0 (node negative by axillary ultrasound), undergoing BCS may be considered for omission of SLN biopsy" 3

---

Which Trial Should Guide Your Practice?

For initial implementation: Use SOUND criteria (≤2 cm, stricter selection) - This provides the most conservative, safest approach with clear oncologic equivalence 1

For broader application: INSEMA criteria may be considered - Larger trial with longer follow-up and detailed quality-of-life data, but includes tumors up to 5 cm (though 90% were T1) 1, 2

The practical reality: Most eligible patients will meet both trial criteria, as the median tumor size in INSEMA was small and outcomes were driven by the T1 population 4

---

Morbidity Reduction - The Primary Benefit

The strongest argument for SLNB omission is the substantial reduction in surgical morbidity without compromising survival 1:

• 69% reduction in lymphedema (1.8% vs 5.7%)
• 43% reduction in mobility restriction
• 52% reduction in chronic pain

Given equivalent oncologic outcomes and superior quality of life, SLNB omission should be offered to all appropriately selected patients meeting trial criteria 1, 2